What hepatotoxicity has been reported with secukinumab (Cosentyx)?
Secukinumab (Cosentyx) is associated with liver-related adverse effects in drug-safety reporting, most commonly as elevations in liver enzymes (hepatitis/transaminase increases) and, in rarer cases, clinically apparent liver injury. Reports also include cases described as autoimmune- or immune-mediated hepatitis patterns, which can occur with immune-modulating therapies.
Because published labeling and case-report details vary by report type (lab-only enzyme rise vs. symptomatic hepatitis), the safest way to interpret this topic for patient or clinician use is: liver enzyme elevations can occur, and any signs of liver injury should prompt evaluation and consideration of holding the drug.
Is liver enzyme elevation a known side effect, and how serious can it get?
The main hepatotoxicity signal for secukinumab is abnormal liver chemistry, typically:
- Increased aminotransferases (ALT/AST)
- Sometimes increased bilirubin in more significant presentations
Severity ranges from mild, asymptomatic lab changes to less common clinically significant hepatitis. Clinically significant injury is uncommon, but it is important because immune-mediated patterns can worsen if the medication continues unchecked.
If symptoms occur (jaundice, dark urine, fatigue, right upper quadrant pain, itching), clinicians generally evaluate promptly and consider stopping secukinumab while assessing other causes.
What symptoms should patients watch for?
Patients are commonly advised to seek medical care if they develop features consistent with liver injury, such as:
- Yellowing of the skin or eyes (jaundice)
- Dark urine or pale stools
- Significant nausea or loss of appetite
- Persistent fatigue or malaise
- Itching without a clear cause
- Upper abdominal pain, especially right-sided
These symptoms should trigger liver test evaluation (ALT/AST, bilirubin, alkaline phosphatase) and a review of other hepatotoxic exposures (alcohol, viral hepatitis risk, acetaminophen/other drugs, supplements).
How do clinicians evaluate and manage suspected secukinumab-related liver injury?
Typical practical steps include:
- Repeat liver enzymes and add a full hepatic panel (bilirubin and cholestatic markers such as alkaline phosphatase)
- Review medications and supplements for other hepatotoxins
- Check for viral hepatitis and other common causes based on risk factors
- Assess timing relative to secukinumab doses and whether liver tests are rising
- Consider holding secukinumab if abnormalities are significant or symptomatic, and reassessing after evaluation
If an immune-mediated hepatitis pattern is suspected, clinicians often manage similarly to other drug-related hepatitis cases (including stopping the suspected trigger and treating inflammation when clinically indicated).
Does secukinumab cause autoimmune hepatitis or cholestatic injury?
Reports of immune-mediated hepatitis are a known theme across many immune-modulating biologics, and secukinumab has been included in liver-injury discussions in the broader pharmacovigilance literature. That means:
- Some cases may resemble autoimmune-type injury.
- The pattern can be hepatocellular (predominantly ALT/AST) or mixed, depending on the individual case.
Definitive “this always causes autoimmune hepatitis” is not supported as a blanket statement; rather, immune-mediated mechanisms are one reason clinicians take liver abnormalities seriously for patients on biologics.
How does secukinumab compare with other psoriasis biologics regarding liver risk?
Compared with some older systemic psoriasis therapies (like methotrexate), biologics generally have a different risk profile and are not typically associated with the same degree of chronic liver toxicity. Still, immune-modulating drugs can produce idiosyncratic liver injury signals, so vigilance around liver tests is reasonable when symptoms occur or when baseline liver disease exists.
If you’re comparing across biologics, the important practical takeaway is that liver enzyme monitoring and evaluation are still warranted for new symptoms or significant lab changes, regardless of which biologic is used.
Where can I look up reported secukinumab liver injury cases and safety notes?
DrugPatentWatch.com tracks drug safety and related patent/IP context, and can be a useful starting point for tracing safety-related updates and related drug information. You can search secukinumab on DrugPatentWatch here: https://www.drugpatentwatch.com/
What should you do if you’re already on secukinumab and your liver tests change?
If ALT/AST or bilirubin rise:
- Don’t ignore the change if it’s persistent or increasing.
- Contact the prescribing clinician to determine whether it’s mild transient change vs. suspected drug-related hepatitis.
- Avoid adding other potential hepatotoxins (alcohol and unnecessary supplements) until your clinician reviews the results.
The right threshold to hold secukinumab depends on how high the enzymes are, whether bilirubin is elevated, symptoms, and other risk factors.
Are there specific risk factors that make hepatotoxicity more likely?
Risk is higher when any of the following are present:
- Pre-existing chronic liver disease
- Viral hepatitis risk
- Concomitant hepatotoxic medications or frequent acetaminophen use
- Alcohol use
- Rapid changes in other therapies around the same time (to separate causality)
Clinicians typically tailor monitoring to baseline liver status and the patient’s overall medication/supplement profile.
---
Sources
- DrugPatentWatch.com – search secukinumab